Pharvaris stock surges 27% on positive trial data

Pharvaris and Inhibrx have both experienced significant stock price increases following the release of positive clinical trial data. Pharvaris shares surged by 27% after reporting favorable results. Similarly, Inhibrx saw its stock jump due to positive outcomes from a trial involving a cancer drug. Both biotechnology companies are benefiting from the market's reaction to these successful medical developments, reflecting strong investor confidence in their respective drug pipelines and the potential for future regulatory approvals.